Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice

Nanotechnology

Volumn 23, Issue 50, 2012, Pages

  Trivedi, Ruchit ^a   Redente, Elizabeth F ^b   Thakur, Ashish ^a   Riches, David W H ^b   Kompella, Uday B ^a,c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d The University of Colorado Denver   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIODISTRIBUTIONS; BLEOMYCINS; C57BL/6 MICE; DRUG EFFECTS; HYDROXYPROLINE CONTENT; INTRATRACHEAL; INTRATRACHEAL INSTILLATION; LOCAL DELIVERY; POLY LACTIDE-CO-GLYCOLIDE; PULMONARY FIBROSIS;

BIOLOGICAL ORGANS; INFORMATION DISSEMINATION; MACROPHAGES; MAMMALS; NANOPARTICLES;

PEPTIDES;

BLEOMYCIN; COLLAGEN; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; POLYGLACTIN; PYRIDONE DERIVATIVE;

ANIMAL; ARTICLE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; IMMUNOLOGY; LUNG; LUNG FIBROSIS; LUNG LAVAGE; MALE; MOUSE; PATHOLOGY; ULTRASTRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE; COLLAGEN; DELAYED-ACTION PREPARATIONS; LUNG; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYGLACTIN 910; PULMONARY FIBROSIS; PYRIDONES;

EID: 84870395437     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/23/50/505101     Document Type: Article

References (48)

1. Selman M et al 2001 Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy Ann. Intern. Med. 134 136-51
2. Raghu G et al 2006 Incidence and prevalence of idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care. Med. 174 810-6
3. du Bois R M 2010 Strategies for treating idiopathic pulmonary fibrosis Nature Rev. Drug Discovery 9 129-40
4. Davies H R and Richeldi L 2002 Idiopathic pulmonary fibrosis: current and future treatment options Am. J. Respir. Med. 1 211-24
5. Mapel D W, Samet J M and Coultas D B 1996 Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future Chest 110 1058-67
6. King T E Jr et al 2009 Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial Lancet 374 222-8
7. Onoda S et al 2005 Drug interaction between gefitinib and warfarin Jpn. J. Clin. Oncol. 35 478-82
8. Taniguchi H et al 2010 Pirfenidone in idiopathic pulmonary fibrosis Eur. Respir. J. 35 821-9
9. Raghu G et al 2008 Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial Am. J. Respir. Crit. Care. Med. 178 948-55
10. Daniels C E et al 2010 Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am. J. Respir. Crit. Care. Med. 181 604-10
11. King T E Jr 2008 Bosentan for idiopathic pulmonary fibrosis Curr. Opin. Invest. Drugs 9 1171-9
12. King T E Jr et al 2008 BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care. Med. 177 75-81
13. Datta A, Scotton C J and Chambers R C 2011 Novel therapeutic approaches for pulmonary fibrosis Br. J. Pharmacol. 163 141-72
14. Demedts M et al 2005 High-dose acetylcysteine in idiopathic pulmonary fibrosis N. Engl. J. Med. 353 2229-42
15. Higashiyama H et al 2007 Receptor-activated Smad localisation in bleomycin-induced pulmonary fibrosis J. Clin. Pathol. 60 283-9
16. Horan G S et al 2008 Partial inhibition of integrin alpha (v)beta6 prevents pulmonary fibrosis without exacerbating inflammation Am. J. Respir. Crit. Care. Med. 177 56-65
17. Ezquerro I J et al 2003 A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury Cytokine 22 12-20
18. Mehrad B, Burdick M D and Strieter R M 2009 Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis Int. J. Biochem. Cell. Biol. 41 1708-18
19. Markart P et al 2010 Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis J. Aerosol Med. Pulm. Drug Deliv. 23 161-72
20. Macias-Barragan J et al 2010 The multifaceted role of pirfenidone and its novel targets Fibrogenesis Tissue Repair 3 16
21. Burghardt I et al 2007 Pirfenidone inhibits TGF-beta expression in malignant glioma cells Biochem. Biophys. Res. Commun. 354 542-7
22. Branton M H and Kopp J B 1999 TGF-beta and fibrosis Microbes Infect. 1 1349-65
23. Hisatomi K et al 2012 Pirfenidone inhibits TGF-beta1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells BMC Pulm. Med. 12 24
24. Kadam R S and Kompella U B 2010 Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve J. Pharmacol. Exp. Ther. 332 1107-20 (New York: New Rochelle)
25. Stephens R H et al 2002 Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a (-/-) mouse intestine J. Pharmacol. Exp. Ther. 303 1095-101
26. Jackson R M and Gomez-Marin O 2011 Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: review of preclinical science and recent clinical trials Transpl. Res. Risk. Manag. 3 55-63
27. Bruss M L et al 2008 Pharmacokinetics and metabolism of intravenous pirfenidone in sheep Biopharm. Drug Dispos. 29 119-26
28. Lu J M et al 2009 Current advances in research and clinical applications of PLGA-based nanotechnology Expert Rev. Mol. Diagn. 9 325-41
29. Sundaram S et al 2009 Targeted drug and gene delivery systems for lung cancer therapy Clin. Cancer Res. 15 7299-308
30. Scheinman R I et al 2011 Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model Nanomedicine 6 1669-82
31. Beck-Broichsitter M et al 2010 Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles J. Aerosol. Med. Pulm. Drug Deliv. 23 47-57
32. Bandi N et al 2005 Intratracheal budesonide-poly (lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo (a)pyrene-fed mouse model J. Pharm. Pharmacol. 57 851-60
33. Verbaan F et al 2003 Intravenous fate of poly (2- (dimethylamino)ethyl methacrylate)-based polyplexes Eur. J. Pharm. Sci. 20 419-27
34. Beck-Broichsitter M et al 2011 Pulmonary drug delivery with nanoparticles Nanomedicine in Health and Disease ed V R Preedy (Boca Raton, FL: CRC Press) pp 229-48
35. Sinha B, Mukherjee B and Pattnaik G 2012 Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study Nanomedicine at press
36. Merkel O M and Kissel T 2012 Nonviral pulmonary delivery of siRNA Acc. Chem. Res. 45 961-70
37. Poyner E A et al 1995 A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery J. Control. Release 35 41-8
38. Albanese A, Tang P S and Chan W C 2012 The effect of nanoparticle size, shape, and surface chemistry on biological systems Annu. Rev. Biomed. Eng. 14 1-16
39. Hamoir J et al 2003 Effect of polystyrene particles on lung microvascular permeability in isolated perfused rabbit lungs: role of size and surface properties Toxicol. Appl. Pharmacol. 190 278-85
40. Pandey R et al 2003 Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J. Antimicrob. Chemother. 52 981-6
41. Okamoto T et al 1970 Experimental pulmonary fibrosis induced by bleomycin Igaku to Seibutsugaku 80 299-301
42. Adamson I Y and Bowden D H 1974 The pathogenesis of bloemycin-induced pulmonary fibrosis in mice Am. J. Pathol. 77 185-97
43. Redente E F et al 2011 Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis Am. J. Physiol. Lung. Cell Mol. Physiol. 301 L510-8
44. Kamata H et al 2011 Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice Exp. Biol. Med. 236 315-24
45. Kawashima M et al 2002 Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury Lung 180 73-89
46. Selman M et al 2004 Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches Drugs 64 405-30
47. Yamashita C M et al 2011 Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis Am. J. Pathol. 179 1733-45
48. Schaefer C J et al 2011 Antifibrotic activities of pirfenidone in animal models Eur. Respir. Rev. 20 85-97